Kisspeptin-10: The Reproductive Hormone Signal Explained

Kisspeptin-10 is a ten-amino-acid fragment of kisspeptin, the peptide encoded by the KISS1 gene that acts as the master switch for the reproductive hormone axis. When it binds its receptor (KISS1R, formerly GPR54) on neurons in the hypothalamus, it triggers release of gonadotropin-releasing hormone (GnRH), which in turn drives luteinising hormone (LH), follicle-stimulating hormone (FSH) and downstream sex steroids. In the UK kisspeptin-10 is sold as a research chemical for laboratory use only and has no MHRA marketing authorisation.

Kisspeptin is unusual among research peptides in that most of the key studies were run in the UK, at Imperial College London, and published in mainstream endocrinology journals. That makes it one of the better-documented compounds in the catalogue. This guide explains the biology, summarises the human infusion studies, compares the two common fragment lengths and sets out the legal position for UK laboratories.

What is kisspeptin-10?

The KISS1 gene was identified in 1996 by a group in Hershey, Pennsylvania, who were looking for genes that suppressed the spread of melanoma; the name is a nod to the town's famous chocolate. The protein product, originally called metastin, is cleaved into a family of peptides sharing the same C-terminal sequence: kisspeptin-54, kisspeptin-14, kisspeptin-13 and kisspeptin-10. All of them end in an arginine-phenylalanine-amide motif that is essential for receptor binding.

Kisspeptin-10 is the smallest of these fragments that retains full activity at KISS1R. Its reproductive role was discovered in 2003, when two independent groups, de Roux and colleagues in PNAS and Seminara and colleagues in the New England Journal of Medicine, reported that people with inactivating mutations in GPR54 failed to go through puberty and had hypogonadotropic hypogonadism. The receptor was intact for everything else; it simply could not receive the kisspeptin signal, and without it the GnRH neurons stayed quiet.

That finding placed kisspeptin upstream of GnRH in the control hierarchy. Kisspeptin neurons in the arcuate nucleus and the anteroventral periventricular region integrate signals from sex steroids, energy status, stress and, as later work showed, the melanocortin system, and translate them into pulses of GnRH. Kisspeptin-10 is the tool most laboratories use to probe that pathway because it is short, easy to synthesise and fully active.

How kisspeptin-10 works in the reproductive axis

The pathway runs in a straight line. Kisspeptin binds KISS1R, a G-protein-coupled receptor, on the surface of GnRH neurons. Receptor activation depolarises the neuron and causes GnRH release into the portal circulation that feeds the anterior pituitary. GnRH stimulates the pituitary gonadotroph cells to secrete LH and FSH, which act on the testes or ovaries to produce testosterone, oestradiol and gametes. Sex steroids then feed back on the kisspeptin neurons, not directly on GnRH neurons, which is why the kisspeptin population is regarded as the site where feedback is computed.

One consequence is that kisspeptin only works if the downstream machinery is intact. In animal models and in humans with GnRH deficiency, kisspeptin has little effect, because the neurons it targets are missing or cannot respond. Another consequence, important for study design, is desensitisation: continuous exposure to kisspeptin in early studies led to tachyphylaxis and a fall in LH, which is one reason later protocols moved to intermittent or pulsatile schedules.

What the human kisspeptin research shows

The first human study was published by Dhillo and colleagues at Imperial in the Journal of Clinical Endocrinology and Metabolism in 2005. Healthy men received a 90-minute intravenous infusion of kisspeptin-54 at a range of rates, and the investigators recorded dose-dependent rises in LH, with smaller increases in FSH and testosterone. A 2007 follow-up in the same journal in women found that the response varied with the menstrual cycle, being largest in the preovulatory phase and much smaller in the early follicular phase.

Kisspeptin-10 itself was characterised in men by George and colleagues in JCEM in 2011. Intravenous boluses from 0.01 to 3 micrograms per kilogram produced a rapid, dose-related LH surge, and a continuous infusion over several hours increased LH pulse frequency, pulse size and circulating testosterone. Jayasena and colleagues reported the same year that kisspeptin-10 showed marked sexual dimorphism: it reliably stimulated LH in men but did so in women only around ovulation. A later direct comparison found that intravenous kisspeptin-10 and kisspeptin-54 released similar amounts of gonadotropin in healthy men, despite kisspeptin-10 having a plasma half-life roughly six times shorter.

The most clinically striking work used kisspeptin-54 rather than -10. In the Journal of Clinical Investigation in 2014, Jayasena and colleagues reported that a single subcutaneous injection of kisspeptin-54 was able to trigger egg maturation in women undergoing IVF, with fertilisation, implantation and live births following in a proportion of the 53 participants. Abbara and colleagues extended this in 2015 to women at high risk of ovarian hyperstimulation syndrome, where the shorter, self-limiting LH surge produced by kisspeptin was seen as a potential safety advantage over conventional triggers.

More recently the same group has looked beyond gonadotropins. Two randomised, placebo-controlled crossover studies in JAMA Network Open, one in 32 premenopausal women (Thurston and colleagues, 2022) and one in 32 men (Mills and colleagues, 2023), all with hypoactive sexual desire disorder, used functional MRI during a kisspeptin-54 infusion. Kisspeptin altered activity in brain regions involved in sexual and attraction processing, and in the men it increased penile tumescence in response to sexual stimuli by up to 56% compared with placebo, with no significant adverse effects reported. These are small mechanistic studies rather than efficacy trials, but they explain why kisspeptin now appears in discussions alongside melanocortin peptides such as PT-141.

Kisspeptin-10 vs kisspeptin-54

The two fragments activate the same receptor with similar potency, so the choice between them in research is mostly about pharmacokinetics and practicality. The table below summarises the differences that appear in the literature.

How kisspeptin-10 is used in laboratory research

Outside the clinical infusion studies, kisspeptin-10 is a standard reagent in reproductive neuroendocrinology. Its short half-life is a feature in this context, since it allows researchers to deliver a clean, brief stimulus and watch the response unfold without lingering receptor occupancy.

• Electrophysiology on hypothalamic slices and cultured GnRH neurons, where kisspeptin-10 is used to characterise KISS1R signalling, calcium responses and desensitisation.
• Pulsatility studies in rodents, sheep and non-human primates that measure LH pulse frequency after bolus or intermittent kisspeptin-10.
• Receptor pharmacology, including structure-activity work that led to longer-acting analogues such as TAK-448 and MVT-602 now in clinical development.
• Metabolic and stress crosstalk studies examining how leptin, ghrelin, cortisol and the melanocortin system modulate kisspeptin neurons.
• Diagnostic research: a 2020 study from Boston (Chan and colleagues, JCEM) reported that the LH response to a kisspeptin challenge helped predict which adolescents with delayed puberty would progress spontaneously.

Is kisspeptin-10 legal in the UK?

Yes. Kisspeptin-10 is legal to buy, sell and possess in the UK as a research chemical. It is not controlled under the Misuse of Drugs Act 1971 and is not a psychoactive substance. What is unlawful is supplying it for human medicinal use, or marketing it with claims about fertility, hormones or sexual function, without a marketing authorisation under the Human Medicines Regulations 2012. No kisspeptin fragment has an MHRA marketing authorisation, and the ongoing clinical trials use investigational material supplied under hospital ethics approval.

It is also worth knowing that the pharmaceutical development of kisspeptin has shifted towards synthetic long-acting KISS1R agonists rather than the native fragments. If a kisspeptin-based medicine is eventually licensed, it is unlikely to be the same molecule sold as a research reagent.

What to check before buying kisspeptin-10 in the UK

Kisspeptin-10 is a short peptide and relatively cheap to synthesise, which means the market is crowded. Because its activity depends entirely on the C-terminal arginine-phenylalanine-amide, a truncated or non-amidated batch would be inactive while still looking plausible on a basic purity trace. That makes identity confirmation particularly important.

1. Ask for a batch-specific certificate of analysis showing HPLC purity and mass-spectrometry identity with the correct molecular weight for the amidated decapeptide. Calibre pens are tested by Janoshik Analytical and COAs are published on the site's COA page.
2. Look for a target purity above 99% and confirm the milligram figure refers to peptide content rather than gross weight.
3. Consider a pre-filled, precision-made pen if the workflow benefits from consistent, ready-to-use volumes rather than reconstituting lyophilised powder.
4. Check the supplier is UK-based, identifiable and contactable, and that its listing makes no medicinal or fertility claims.
5. Store kisspeptin-10 refrigerated and protected from light; like most short peptides it degrades with heat and repeated freeze-thaw cycles.

Summary

Kisspeptin-10 is the working fragment of the peptide that sits at the top of the reproductive hormone axis. Its role was established by human genetics in 2003 and mapped in detail by two decades of infusion studies, most of them run in London. It stimulates GnRH and therefore LH, FSH and sex steroids, with a short half-life that makes it a precise research tool. For UK laboratories it is legal to buy as a research chemical, has no MHRA licence, and should be sourced with a certificate of analysis that confirms both purity and the amidated C-terminus on which its activity depends.